Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

"FDA FOIA staff, including those working on litigation involving CBER, were impacted as part of HHS' reorganization," Nixon ...

The decision had been expected by April 1, but the agency now says it needs more information before moving forward.

The company has also filed for FDA approval of its flu+Covid combination ... MRNA technology is already used in Moderna’s and Pfizer/BioNTech’s currently licensed Covid-19 vaccines, which ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Vaccine stocks have been under significant pressure since the FDA's top vaccine official resigned. Seeking Alpha analysts ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

The U.S. Food and Drug Administration has delayed granting full approval ... from Pfizer/BioNTech and Moderna, has been subject to emergency use authorization since 2022. But with FDA action ...

Pfizer and Moderna received full approval for their mRNA Covid-19 vaccines for certain age groups during the pandemic. Kennedy petitioned the FDA in May 2021 to revoke emergency authorizations for ...

It comes on the heels of the FDA's top vaccine scientist Peter Marks' exit from the agency, which will be effective April 5.